AEON Biopharma, Inc.

AEON Biopharma, Inc. (ticker: AEON) is a clinical-stage biopharmaceutical company focused on developing botulinum toxin complex therapeutics for a range of therapeutic and medical aesthetics indications. The company became publicly listed following its de-SPAC business combination with Priveterra Acquisition Corp., a blank check company whose SPAC IPO priced in 2021 under the sponsorship of Priveterra LLC. The merger closed in 2022, after which the combined entity began trading under the AEON ticker on NYSE American. As of the 10-Q filed with the SEC in November 2022, the company was operating as a post-combination public entity in the healthcare and biotechnology sector. Visit SpacDesk and sign up for full data, including SEC filings, shareholder composition, and deal timeline analytics for AEON and hundreds of other SPAC transactions.